modifi
vaccinia
viru
ankara
antigen
deliveri
system
best
use
potenti
ingo
drexler
carolin
staib
gerd
sutter
safetytest
modifi
vaccinia
viru
ankara
mva
establish
potent
vector
system
develop
candid
recombin
vaccin
versatil
vector
system
recent
demonstr
rapid
product
experiment
mva
vaccin
immun
sever
acut
respiratori
syndrom
associ
coronaviru
promis
result
also
obtain
deliveri
epsteinbarr
viru
human
cytomegaloviru
antigen
clinic
test
mva
vector
vaccin
immunodefici
viru
papilloma
viru
plasmodium
falciparum
melanoma
moreov
mva
consid
prime
candid
vaccin
safer
protect
orthopoxviru
infect
thu
vector
develop
challeng
dilemma
vaccinolog
immun
poxviru
biothreat
seem
possibl
yet
right
choic
made
benefici
use
poxvirus
engin
express
foreign
gene
establish
tool
target
protein
synthesi
vaccin
develop
biomed
research
larg
packag
capac
recombin
dna
precis
virusspecif
control
target
gene
express
lack
persist
genom
integr
host
high
immunogen
vaccin
eas
vector
vaccin
product
import
featur
enabl
success
stori
concern
safeti
poxvirus
includ
vaccinia
viru
vv
former
smallpox
vaccin
address
use
virus
replicationdefect
human
cell
among
modifi
vaccinia
viru
ankara
mva
consid
one
viru
strain
choic
preclin
clinic
research
histor
mva
develop
attenu
serial
passag
primari
chicken
embryo
cell
serv
safer
vaccin
smallpox
review
see
passag
tissu
cultur
mva
lost
broad
cellular
host
rang
vv
unabl
product
grow
mani
cell
mammalian
origin
concurr
avirul
mva
laboratori
anim
entir
unproblemat
use
primari
smallpox
vaccin
human
found
high
safeti
profil
recombin
mva
depend
natur
insert
target
gene
use
condit
biosafeti
level
capac
produc
similar
level
viral
recombin
antigen
compar
replicationcompet
virus
relev
featur
mva
vaccin
recent
year
signific
progress
made
develop
mva
vaccin
technolog
review
inform
newest
develop
gener
recombin
mva
illustr
princip
featur
impact
mva
immunogen
also
describ
advanc
made
preclin
clinic
evalu
mva
secondgener
poxviru
vaccin
deliveri
heterolog
antigen
target
infecti
diseas
cancer
final
consid
compat
differ
mva
exploit
rais
question
futur
use
prioriti
given
recombin
mva
among
promis
live
viral
vector
system
wellestablish
safeti
versatil
product
heterolog
protein
recent
engin
recombin
mva
synthes
compon
necessari
assembl
deliveri
alphaviru
replicon
particl
serv
eleg
exampl
applic
purpos
howev
gener
mva
vector
straightforward
requir
singl
genom
insert
mediat
homolog
recombin
viru
genom
dna
plasmid
carri
one
two
recombin
gene
place
control
vvspecif
promot
figur
site
natur
occur
delet
within
mva
genom
classic
gene
loci
encod
vv
protein
thymidin
kinas
hemagglutinin
serv
site
insert
recombin
gene
sequenc
sever
wellestablish
techniqu
clonal
isol
recombin
mva
involv
coexpress
chromogen
agent
eg
escherichia
coli
bgalactosidas
bglucuronidas
provid
resist
antimicrobi
eg
e
coli
xanthineguaninephosphoribosyltransferas
overview
see
recent
method
reli
growth
select
recombin
mva
develop
protocol
take
advantag
select
propag
cell
cultur
nonpermiss
nonrecombin
mva
one
protocol
vv
host
rang
gene
transient
introduc
mva
genom
recombin
mva
subsequ
isol
rabbit
kidney
cell
clonal
isol
vector
viru
marker
gene
remov
viral
genom
bear
advantag
marker
reus
subsequ
gener
mva
recombin
virus
harbor
multipl
gene
insert
anoth
recent
develop
host
rang
select
techniqu
reli
growth
rescu
mutant
mva
chicken
embryo
fibroblast
cef
cell
lack
interferon
resist
gene
mva
antigen
deliveri
system
drexler
staib
sutter
unabl
grow
cef
stabl
reinsert
gene
togeth
target
gene
sequenc
allow
quick
isol
mva
recombin
virus
cef
highli
attenu
mva
primarili
consid
provid
mean
safer
vaccin
smallpox
although
knowledg
avirul
immunostimul
capac
infect
experi
multipl
anim
model
systemat
effort
character
molecular
basi
mva
vaccin
immunogen
date
recent
past
import
achiev
includ
character
mva
molecular
life
cycl
upon
infect
nonpermiss
mammalian
cell
elucid
mva
genom
understand
mva
lost
relev
poxviru
immun
evas
gene
target
innat
host
respons
base
cytokin
chemokin
function
consequ
defect
inhibitori
viru
gene
like
respons
mvaspecif
induct
host
cytokin
synthesi
propos
decad
ago
review
see
interestingli
inactiv
vv
interferon
resist
gene
mva
genom
result
enhanc
product
type
interferon
cef
suggest
capac
mva
stimul
innat
respons
may
enhanc
ration
mutagenesi
assum
immunostimul
contribut
particular
immunogen
mva
might
compens
advantag
live
replicationcompet
vv
sustain
antigen
product
contrast
virus
eg
member
herpesviru
famili
mva
replicationcompet
vv
appear
specif
interfer
host
cell
antigen
process
present
allow
appar
unimpair
induct
adapt
immun
respons
assumpt
agreement
find
vvspecif
humor
cellular
immun
detect
decad
primari
vaccin
recent
compar
convent
vv
vaccin
mva
vaccin
found
elicit
similar
pattern
vvspecif
immun
respons
provid
protect
experiment
orthopoxviru
infect
requir
inocul
higher
dosag
compar
monitor
epitopespecif
tcell
respons
direct
vaccinia
viru
recombin
antigen
quantit
epitopespecif
cell
perform
follow
one
immun
human
hlaa
mice
iu
either
wildtyp
mva
mvawt
recombin
mvatyr
express
human
tumor
antigen
tyrosinas
respect
ten
day
post
vaccin
peptidespecif
intracellular
cytokin
releas
splenocyt
determin
stimul
vaccinia
epitop
vv
tyrosinas
tyr
peptid
cell
analyz
flow
cytometri
presenc
peptidespecif
activ
low
cell
magnitud
specif
induc
tcell
respons
depict
cell
shift
lower
right
indic
percentag
number
blue
interferongsecret
cell
within
cell
popul
much
previou
research
dedic
develop
mva
candid
recombin
vaccin
multipl
viru
infect
human
includ
caus
aid
influenza
earli
childhood
respiratori
diseas
measl
japanes
enceph
dengu
fever
review
see
effect
vaccin
aid
urgent
need
recombin
mva
produc
immunodefici
viru
antigen
among
first
vector
virus
evalu
candid
vaccin
human
substanti
data
studi
differ
simian
immunodefici
viru
siv
simian
human
immunodefici
viru
shiv
chimera
siv
hiv
infect
model
strongli
support
thorough
clinic
evalu
mvabas
vaccin
use
heterolog
primeboost
strategi
includ
mva
vaccin
deliv
multipl
siv
hiv
antigen
prove
success
elicit
antibodi
highlevel
cytotox
tcell
respons
macaqu
immun
respons
effect
control
mucos
challeng
shiv
virus
significantli
reduc
viral
load
challeng
infect
neutralizationresist
highli
replicationcompet
importantli
recent
data
suggest
sivhivspecif
mucos
immun
boost
peripher
mva
immun
oral
prime
salmonella
vector
vaccin
intranas
inocul
recombin
mva
stimul
immunodefici
virusspecif
immun
genit
rectal
tract
elicit
potent
mucos
immun
induct
broadli
virusneutr
antibodi
respons
import
mileston
still
reach
deriv
success
hiv
vaccin
princip
capac
mva
elicit
highli
effect
virusneutr
antibodi
respons
highlight
character
vector
vaccin
sever
acut
respiratori
syndrom
sar
coronaviru
human
cmv
success
engin
mva
express
sar
coronaviru
spike
protein
also
demonstr
suitabl
vector
system
readili
respond
potenti
threat
rapidli
emerg
infecti
diseas
recent
develop
recombin
mva
deliv
multipl
cmv
antigen
repres
promis
candid
clinic
test
mvabas
tcell
vaccin
studi
also
mirror
gener
interest
develop
mva
vector
vaccin
human
herpesviru
infect
potenti
activ
robust
cellular
major
histocompat
complex
mhc
class
iand
iirestrict
tcell
respons
recombin
antigen
made
mva
vaccin
attract
immunotherapeut
approach
cancer
select
intracellular
parasit
bacteri
infecti
diseas
experiment
cancer
therapi
virusassoci
malign
seem
predestin
target
mva
vaccin
taylor
cowork
demonstr
immunogen
epsteinbarr
virusassoci
nasopharyng
carcinoma
vaccin
reactiv
epsteinbarr
virusspecif
memori
cell
vitro
recent
corona
gutierrez
colleagu
show
evid
therapeut
efficaci
mva
vaccin
deliv
human
papillomaviru
hpv
antigen
cervic
cancer
associ
hpv
infect
phase
iii
clinic
trial
vaccin
base
recombin
mva
express
differ
tumorassoci
antigen
specif
varieti
cancer
current
test
mice
human
often
combin
cytokin
costimulatori
molecul
measur
circumv
immun
inhibitori
signal
blockad
cellular
adjuv
like
dendrit
cell
enhanc
immun
respons
antigen
like
tolerogen
selfprotein
major
effort
underway
develop
vaccin
malaria
caus
plasmodium
spp
parasit
preclin
heterolog
primeboost
immun
regimen
elicit
strong
tcell
immun
shown
substanti
protect
mous
malaria
challeng
model
plasmodium
berghei
plasmodium
yoelii
addit
safeti
immunogen
establish
clinic
trial
human
volunt
experiment
natur
expos
plasmodium
falciparum
recent
first
primeboost
vaccin
tuberculosi
combin
dna
classic
bacil
rin
vaccin
recombin
mva
express
mycobacterium
tuberculosi
antigen
prove
protect
mice
recombin
mva
prime
candid
poxviru
vector
gener
new
vaccin
infect
tumor
portrait
viru
combin
desir
element
highlevel
biolog
safeti
abil
activ
appropri
innat
immun
mediat
upon
vaccin
capac
deliv
substanti
amount
heterolog
antigen
adopt
uptod
methodolog
conveni
vector
gener
vector
qualiti
control
vector
vaccin
immun
monitor
increas
pace
develop
bring
recombin
mva
vaccin
clinic
trial
initi
studi
test
mva
vaccin
prophylaxi
immunotherapi
aid
malaria
human
papilloma
virusassoci
cancer
melanoma
alreadi
complet
tabl
first
result
overal
encourag
confirm
clinic
safeti
importantli
howev
also
demonstr
clinic
efficaci
despit
intrins
difficulti
associ
target
diseas
renew
interest
develop
mva
candid
vaccin
orthopoxvirusrel
biothreat
like
provid
basi
feasibl
largescal
manufactur
mva
vaccin
inde
first
studi
suggest
mva
would
provid
suitabl
orthopox
vaccin
necessari
use
recombin
mva
simultan
provid
immun
smallpox
propos
nevertheless
one
keep
mind
hasti
populationwid
smallpox
vaccin
might
desir
high
level
antivector
immun
could
limit
futur
potenti
poxvirusbas
vector
vaccin
urgent
need
prophylaxi
therapi
uncontrol
infecti
diseas
cancer
emerg
infect
recent
data
phase
clinic
trial
treatment
metastat
melanoma
indic
vaccin
mvatransduc
dendrit
cell
vivo
activ
tcell
respons
direct
recombin
antigen
tyrosinas
recent
identifi
epitop
within
vaccinia
viru
envelop
antigen
immunogen
highli
attenu
mva
smallpox
vaccin
protect
monkeypox
natur
studi
compar
mva
standard
dryvax
vaccin
monkeypox
virusmacaqu
challeng
model
demonstr
similar
immunogen
substanti
protect
capac
mva
vaccin
work
repres
import
step
develop
mva
secondgener
smallpox
vaccin
